Small Cap Feast

26th September 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
Sivota plc has re-joined the Main Market following a RTO
Off The Menu:
No leavers today.

What’s Cooking In The IPO Kitchen?

Streaks Gaming plc, a UK-based provider of conversational gaming products intends to join the Standard Segment of the Main Market this autumn. The flotation is expected to value Streaks at approximately £10.2m (pre-money) and will make it the first LSE-listed “pure-play” conversational gaming company. Raising between £5-10m.

Independent Living REIT plc, intends to float on the Premium Segment of the Main Market. The Company’s investment objective is to address the shortage of high-quality supported housing, delivering capital growth and inflation linked income returns for its investors whilst providing a fair deal for society through savings for the UK taxpayer, and improved outcomes for residents. Raising £150m. Expected 4 October 2022.

The Sustainable Farmland Trust PLC, intends to float on the Premium Segment of the Main Market. The Company invests in a diversified portfolio of farmland and related agriculture-focused assets predominantly located in the US.

Raising £200m. Timing TBC.

Welkin China Private Equity, newly established closed-ended investment company dedicated to investing in unquoted Chinese companies, intends to join the Premium Segment of the Main Market. The Company is targeting a raise of up to US$300m.

Georgina Energy, focusing on the exploration, development and monetisation of helium, hydrogen and hydrocarbon interests located in Australia intends to join AIM. Georgina Energy has two principal onshore interests: (1) Mount Winter Prospect in the Amadeus Basin in Northern Australia, which the Company has a right to earn an initial 75% interest; (2) Hussar Prospect, 100% owned by the Company, located in the Officer Basin in Western Australia. Expected late September.

Altona Rare Earths, the AQSE-listed mining exploration company focused on rare earth elements projects in Africa, intends to join the Main Market. The trading of its ordinary shares on the AQSE Growth Market will be cancelled simultaneously and its EPIC will be changed from AQSE:ANR to REE. Conditionally raised £1.1m. Expected late September.

Breakfast Buffet

Brighton Pier Group 57p £21.3m (PIER.L)

The operator of premium bars announce its unaudited results for the 52 weeks ended 26 June 2022. The Group reported record revenues at £40.1m, up 197% (2021: £13.5m), driven by strong trading across all divisions. A consistent gross margin performance, combined with temporary reductions in VAT and business rates, has enabled the Group to maximise earnings and repay debt— net debt down by 62% to £5m. Whilst the trading this year has continued to be strong, the Board looks towards the second half of 2022 with caution amid economic uncertainties.

Christie Group 120p £31.8m (CTG.L)

The provider of Professional & Financial Services and Stock & Inventory Systems & Services to the hospitality, leisure, healthcare, medical, childcare & education and retail sectors, announces its interim results for the six months ended 30 June 2022. Revenues grew by 18% to £33.7m (H1 2021: £28.6m), and operating profit increased by 26% to £2.3m (H1 2021: £1.8m). During the period Christie repaid a further £1.0m of CLBILS loan. The Group has received extensive interest in the Four Seasons Healthcare Group and the first round bid process will conclude in early Autumn. Despite the economic clouds gathering, Christie anticipates a successful full year.

CPP Group 155p £13.7m (CPP.L)

The provider of assistance and insurance products, announces its interim results for the six months ended 30 June 2022. Group revenue from continuing operations increased by 18% to £77.8m (H1 2021 restated: £65.7m) and core revenues increased by 26% to £69.5m (H1 2021: £55m). Profit before tax from continuing operations increased to £1.3m (H1 2021 restated: £0.5m loss). The Board remains confident in the outlook for its core operations. However, the structural issues pertaining to its Legacy Business and associated IT costs will have some impact on overall performance. CPP will provide further guidance in due course.

Eden Research 4.7p £17.7m (EDEN.L)

The company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that it has received regulatory approval from the United States Environmental Protection Agency (EPA), for all 5 petitions submitted, covering the Company’s 3 active ingredients (eugenol, geraniol and thymol) and 2 formulated products (Mevalone ® and Cedroz™). The approval will open revenue opportunities for Eden. The Board expects the registration of Eden’s developmental insecticide will follow a shortened timeline as it is based upon the now-approved active ingredients. Eden will pursue registration of this new product in due course based upon the outcome of field trials.

Genedrive 12.3p £11.3m (GDR.L)

The near patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (NICE) has transferred the evaluation of the Genedrive® MT-RNR1 test to a new Early Value Assessment Programme (EVA). EVA is a new review process, created to drive innovation by actively drawing in digital products, medical devices and diagnostics that address national unmet needs. The EVA allows the NICE diagnostics advisory committee to consider the technology much faster, which will result in a published report in a six-month timeframe instead of the initial 63 weeks. A provisional schedule has been published by NICE which indicates the consultation process will occur in February 2023.

Kingswood Holdings 23p £49.9m (KWG.L)

The international, fully integrated wealth and investment management group, announces the proposed strategic acquisition of Moloney Investments Ltd. (MMPI), a leading financial advice firm based in Dublin, Ireland. On a pro forma basis, for the 12 months to 30 April 2022, MMPI had EBITDA of EUR 4m and in excess of EUR 700m assets under advice. Following receipt of regulatory approval, Kingswood will acquire 70% of MMPI for a total cash consideration of EUR 25.8m, with the existing shareholders retaining the remaining 30%. Both management teams will work together to grow MMPI and the wider Kingswood group organically and through further acquisitions.

One Media IP Group 7.3p £16.1m (OMIP.L)

The digital media content owner and provider announces that it has refinanced its £1.9m of outstanding unsecured loan notes held by British Growth Fund, which carried a fixed interest rate of 7%. The refinancing is by way of a secured facility from Coutts & Co. priced at base rate plus 3.5%, amortising on a straight-line basis over 5 years. The Coutts facility is on more traditional bank lending terms and contains fewer restrictions on the operations of the business.

Pittards 54.5p £6.5m (PTD.L)

The producer of technically advanced leather and luxury leather goods for retailers, manufacturers and distributors, announces its interim results for the six month ended 30 June 2022. Group revenues increased 7% to £10.37m (H12021: £9.66m) and profit before taxation grew 31% to £0.34m (H1 2021: £0.26m). EBITDA was £0.83m, an 11% improvement (H1 2021: £0.75m). Net debt was £11.18m (H1 2021: £10:04m). Pittards continues to see more opportunities than risk in the current climate and are cautiously optimistic looking forward.

SolGold 16.4p £376.6m (SOLG.L)

The exploration company focussed on the discovery, definition and development of world-class copper-gold deposits will host a site visit for analysts and institutional investors at its Cascabel project in northern Ecuador on 26 September 2022. The site visit presentation is available on the Company’s website at: investors-center/

Steppe Cement 32.5p £71.2m (STCM.L)

The investment holding with its primary business in the production of cement, located in the Karaganda region of the Republic of Kazakhstan, reports its interim results. The Company increased its prices during the first half of 2022, with the average ex-factory price up from 16,571 KZT /tonne (USD39 per tonne) to 20,485 KZT/tonne (USD 45 per tonne). Consolidated profit after tax increased 65% to US$10.2m. Selling expenses per tonne decreased in USD terms by 20% due to increased sales to markets closer to the factory. Steppe Cement maintained its local market share at 14.5% in 1H 2022 and expects to maintain or increase this share for the full year.

26 September 2022
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram